Abstract
Objectives This study aimed to evaluate the costs of respiratory-syncytial virus (RSV)-related hospitalizations in children under 3 years old in Belgium for hospitals and health insurance, and to identify factors influencing costs.
Study design This retrospective cohort study used data from 16 French-speaking hospitals in Belgium, covering January 1, 2018, to December 31, 2019. RSV diagnoses for children under three were identified using International Classification of Diseases-Tenth Revision (ICD-10) codes, resulting in 2,176 hospitalizations analyzed for cost assessment. Hospital and health insurance costs were derived from administrative and billing data, adjusted for inflation, and analyzed using descriptive and inferential statistics, including regression models to assess cost factors.
Results RSV prevalence among pediatric hospitalizations peaked at 12.9% in 2018 and 10.0% in 2019, with children under 3 years showing a prevalence of 16.7% both years. Of the 2,176 RSV-related hospitalizations, 61.8% were in children under one year, and 28.6% had readmissions within a year. The median length of stay (LOS) was 3.67 days, with a median hospital cost of €2,924 and a median health insurance cost of €2,221 per stay. Factors associated with higher costs included longer LOS, severe diagnosis-related group category, pediatric intensive care unit admission, and non-invasive ventilation use, with costs generally lower for children aged 1-2 years.
Conclusions This study highlights the significant financial burden of RSV hospitalization in Belgium, with costs exceeding €25 million annually. This emphasizes the need for preventive measures and better resource allocation to reduce the economic impact of RSV on healthcare systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The inpatient records used in the retrospective study were fully anonymized by the hospitals and the research team did not have any access to medical files. The study was approved by the Ethics Committee of the Erasmus Hospital in Brussels (reference: N2023/047). Signed informed consent was obtained from all individual participants included in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The dataset used and analyzed in this manuscript is available from the corresponding author upon reasonable request.
Abbreviations
- APR-DRG
- all patients refined disease-related group
- CI
- confidence interval
- DRG
- disease-related group
- ICU
- intensive care unit;
- ICD-10
- International Classification of Diseases-10th revision
- IQR
- interquartile range
- LOS
- length of stay
- NICU
- neonatal intensive care unit
- PICU
- pediatric intensive care unit
- RSV
- respiratory syncytial virus
- SOI
- severity of illness
